China Sky One Medical (CSKI) Submits Application to Perform Clinical Trials for Two New Eye Drugs to SFDA
More News related to CSKI
- China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
- China Sky One Medical (CSKI) Posts Q3 EPS of $0.74, Tops Views by 8c
- China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results
- Trading Radar for 11/17: Home Depot (HD), Saks (SKS), Target (TGT), Autodesk (ADSK), La-Z-Boy (LZB) Report
- Semi-Annual Changes to the NASDAQ Biotechnology Index
More News related to Corporate News
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
China Sky One Medical (Nasdaq: CSKI) announced that the Company has finished the required research for two new generic drugs for eye treatment and submitted application to the State Food and Drug Administration (SFDA) in China to perform clinical trials.
Compound Allantoin Vitamin B-E and Aminoethylsulfonic Acid eye drops are used to cure chronic conjunctivitis, cornea trauma and congestive conjunctiva. Dextran and Glycerol eye drops are used to eliminate dryness, sharp pain, and other irritation of the eye. Currently there are no domestic pharmaceutical companies in China that are able to produce Dextran and Glycerol eye drops. Both eye products represent the latest medical technology available worldwide and the Company believes they have promising market potential.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.39Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
